ANVS Stock Summary and Trading Ideas (Annovis Bio | NYSE:ANVS)

Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.

Annovis Bio trades on the NYSE stock market under the symbol ANVS.

As of January 30, 2026, ANVS stock price declined to $2.70 with 528,734 million shares trading.

ANVS has a beta of 2.56, meaning it tends to be more sensitive to market movements. ANVS has a correlation of 0.13 to the broad based SPY ETF.

ANVS has a market cap of $71.56 million. This is considered a Micro Cap stock.

In the last 3 years, ANVS traded as high as $23.89 and as low as $1.11.

The top ETF exchange traded funds that ANVS belongs to (by Net Assets): VTI, VXF.

ANVS has underperformed the market in the last year with a price return of -44.8% while the SPY ETF gained +16.2%. However, in the short term, ANVS had mixed performance relative to the market. It has outperformed in the last 3 months, returning +22.7% vs +1.0% return in SPY. But in the last 2 weeks, ANVS shares have been beat by the market, returning -15.6% compared to an SPY return of 0.0%.

ANVS support price is $2.66 and resistance is $2.96 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANVS shares will trade within this expected range on the day.